Studies carried out in preclinical models of mesothelioma demonstrated that CAFs contribute to tumor growth and resistance to therapy mainly by inhibiting cytotoxic T cell influx in the tumor tissue and that the use of chimeric antigen receptor‐transduced T cells targeted to cells expressing fibroblast activation protein (FAP) can reduce the tumor growth in an animal model.29, 30. This evidence concerns the gene FAP and mesothelioma.